Cytokinetics, Incorporated (CYTK)

Market Cap	10.38B +134.7%
Revenue (ttm)	105.82M +450.6%
Net Income	-829.61M
EPS	-6.84
Shares Out	135.77M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,399,086
Open	75.65
Previous Close	75.18
Day's Range	73.00 - 76.78
52-Week Range	29.81 - 80.20
Beta	0.38
Analysts	Buy
Price Target	104.70 (+36.95%)
Earnings Date	May 5, 2026

About CYTK

Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in h...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Apr 29, 2004
• Employees: 673
• Stock Exchange: NASDAQ
• Ticker Symbol: CYTK
• Website: https://www.cytokinetics.com

Financial Performance

In 2025, Cytokinetics's revenue was $88.04 million, an increase of 376.56% compared to the previous year's $18.47 million. Losses were -$784.96 million, 33.2% more than in 2024.

Analyst Summary

According to 22 analysts, the average rating for CYTK stock is "Buy." The 12-month stock price target is $104.7, which is an increase of 36.95% from the latest price.

Price Target

$104.7

(36.95% upside)

Analyst Consensus: Buy